| |
|
|
|
|
|
|
|||
|
Blood, 1 July 2008, Vol. 112, No. 1, pp. 100-110. Prepublished online as a Blood First Edition Paper on March 12, 2008; DOI 10.1182/blood-2007-07-104455.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Nuclear translocation of urokinase-type plasminogen activator1 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia; 2 Russian Cardiology Research Center, Moscow, Russia; 3 Hannover Medical School, Hannover, Germany; 4 Department of Pharmacology, University of Pennsylvania, Philadelphia; and 5 Department of Clinical Biochemistry, Hadassah University Hospital and Hebrew University-Hadassah Medical School, Jerusalem, Israel
Urokinase-type plasminogen activator (uPA) participates in diverse (patho)physiological processes through intracellular signaling events that affect cell adhesion, migration, and proliferation, although the mechanisms by which these occur are only partially understood. Here we report that upon cell binding and internalization, single-chain uPA (scuPA) translocates to the nucleus within minutes. Nuclear translocation does not involve proteolytic activation or degradation of scuPA. Neither the urokinase receptor (uPAR) nor the low-density lipoprotein-related receptor (LRP) is required for nuclear targeting. Rather, translocation involves the binding of scuPA to the nucleocytoplasmic shuttle protein nucleolin through a region containing the kringle domain. RNA interference and mutational analysis demonstrate that nucleolin is required for the nuclear transport of scuPA. Furthermore, nucleolin is required for the induction smooth muscle
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||